Tizona Therapeutics Announces Expansion of Phase 1b Clinical Trial to Evaluate TTX-080 in Combination with EGFR Inhibitor Cetuximab and Chemotherapy in Advanced Colorectal Cancer
October 31, 2024 08:30 ET
|
Tizona Therapeutics Inc
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a privately held, clinical-stage company developing cancer immunotherapies, today announced the initiation...
Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024
May 23, 2024 17:00 ET
|
Tizona Therapeutics Inc
TTX-080 plus EGFR Inhibitor Cetuximab Demonstrated Promising Evidence of Clinical Activity in Patients with Biomarker-Defined Metastatic Colorectal Cancer and Locally Advanced/Metastatic Head and Neck...
Tizona Appoints Christine O’Brien as Chief Executive Officer
September 15, 2020 09:00 ET
|
Tizona Therapeutics Inc
-- Transaction with Gilead Sciences Closed -- -- Tizona Advances TTX-080, a Novel Anti-HLA-G Antibody, with First Patients Treated in Phase I Study – SOUTH SAN FRANCISCO, Calif., Sept. 15, 2020 ...
Trishula Therapeutics Established to Advance Novel TTX-030, an Anti-CD39 Antibody, Being Evaluated in Phase 1/1B Study in Advanced Cancers
August 26, 2020 09:00 ET
|
Tizona Therapeutics Inc; Trishula Therapeutics
-- Trishula to Continue Development of TTX-030 in collaboration with AbbVie -- SOUTH SAN FRANCISCO, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Today Trishula Therapeutics, a clinical stage,...
Tizona Initiates Clinical Development of TTX-080 in Advanced Cancers
June 25, 2020 06:00 ET
|
Tizona Therapeutics Inc
-- IND Cleared by US FDA with Study Enrollment to Begin in Q3 2020 -- -- First Anti-HLA-G Antibody into the Clinic -- SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Tizona...
Tizona to Present at The Cowen and Company 40th Annual Healthcare Conference
February 19, 2020 09:00 ET
|
Tizona Therapeutics Inc
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a clinical stage, privately held company developing first-in-class cancer immunotherapies, announced today...
Tizona Appoints Joyson Karakunnel, MD, MSc, FACP as Senior Vice President and Chief Medical Officer
July 11, 2019 09:00 ET
|
Tizona Therapeutics Inc
SOUTH SAN FRANCISCO, Calif., July 11, 2019 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a clinical stage, privately held immunotherapy company, today announced the appointment of Joyson...
Tizona Elects Daniel K. Spiegelman to Its Board of Directors
May 15, 2019 16:00 ET
|
Tizona Therapeutics Inc
SOUTH SAN FRANCISCO, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a privately held immunotherapy company, today announced the appointment of Daniel K. Spiegelman to its Board...
Tizona Announces Initiation of Phase 1/1b Study with Novel Cancer Immunotherapy TTX-030 and First Public Presentation of Pre-Clinical Data with TTX-030 at AACR 2019
March 27, 2019 09:00 ET
|
Tizona Therapeutics Inc
SOUTH SAN FRANCISCO, Calif., March 27, 2019 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a privately held immunotherapy company, today announced that it has begun enrolling patients in its Phase...
Tizona Therapeutics Appoints Scott Clarke as Chief Executive Officer and Provides Update on Regulatory Milestone for its First-in-Class CD39 program in Cancer
January 03, 2019 09:00 ET
|
Tizona Therapeutics Inc
– New Leader to Guide Immunotherapy Biotech in its Next Phase of Growth – – FDA Accepts Tizona’s Investigational New Drug Application for TTX-030 – SOUTH SAN FRANCISCO, Calif., Jan. 03, 2019 ...